Clomiphene

Clomiphene citrate (Clomid, Serophene) is a selective estrogen receptor modulator (SERM) historically prescribed for ovulation induction in female infertility. In male endocrinology and AAS protocol design, it functions as an HPTA-recovery agent through hypothalamic ER antagonism — the same mechanism as tamoxifen but with a critical pharmacokinetic distinction that produces the documented side-effect signature.

The racemic mixture problem:

Clomiphene as marketed is a 60:40 racemic mixture of two stereoisomers with substantially different pharmacology:

– Enclomifene (60%): pure ER antagonist with serum half-life of approximately 10 hours. The therapeutic fraction — produces the desired hypothalamic feedback-brake removal and LH/FSH restoration.
– Zuclomifene (40%): weak partial agonist with serum half-life exceeding 14 days. Accumulates across a multi-week course and produces sustained partial-agonist activity at central ER that is the source of the documented side-effect signature.

The accumulation matters. By week 3–4 of standard PCT clomiphene protocol, serum zuclomifene reaches steady-state at concentrations producing measurable central effects: visual disturbances (phosphenes, transient colour shifts, occasional persistent visual field changes documented in the oncology literature), mood effects collectively termed “clomid fog” (depression, anxiety, irritability, anhedonia), and partial estrogenic effects in some peripheral tissues that complicate the clean PCT picture.

Pure enclomifene as alternative:

Pure enclomifene is available in some markets (Androxal, EnclomOne, occasional pharmacy compounded preparations). The compound delivers the same HPTA-restoration mechanism without the zuclomifene accumulation issue. Side-effect profile is substantially cleaner; visual and mood effects are reduced or absent.

For users with prior “clomid fog” experience or who anticipate sensitivity to the zuclomifene signature, pure enclomifene or tamoxifen substitution is the defensible choice.

Standard protocol:

– 50 mg/day weeks 1–2, then 25 mg/day weeks 3–4
– Timing: start 14 days post-last testosterone enanthate (matched to ester clearance)
– Total course: 4 weeks; extend to 6 weeks for longer cycles or stalled recovery
– Often combined with tamoxifen 20 mg/day for redundant SERM coverage

Pharmacology details:

Clomiphene is metabolised primarily by CYP3A4 and CYP2D6, producing 4-hydroxyclomiphene as an active metabolite. Pituitary effect onset is rapid — LH and FSH rise within 5–7 days of initiation. Peak serum testosterone response: 2–3 weeks into the course.

Male TRT applications use clomiphene at lower dose (25 mg every other day to 50 mg/day) for chronic HPTA support in users wanting to avoid exogenous testosterone replacement. Katz et al. 2012, BJU International documented the long-term efficacy and tolerability of clomiphene as TRT alternative.

Side-effect profile:

– Visual disturbances: 1–2% of users in oncology data; higher in extended-course PCT users. Phosphenes are most common; persistent visual field changes are rare but warrant immediate discontinuation.
– Mood effects: “clomid fog” in 5–15% of users; resolves within 2–3 weeks of cessation. Pre-existing depression or anxiety predisposes.
– Hot flashes: common, transient.
– Headache, nausea: occasional.
– Visual side effects warrant ophthalmology referral if persistent.

When clomiphene is the appropriate choice:

Clomiphene retains a niche where its pituitary effect profile is preferred — typically users who have tried tamoxifen monotherapy with inadequate LH/FSH restoration response, or users on TRT alternative protocols where chronic central stimulation is the goal. For standard 4-week post-cycle PCT, tamoxifen monotherapy is the cleaner default; clomiphene addition or substitution is reasonable based on individual response.